BR112015002528A2 - combinação de inibidor de pi3k e inibidor de c-met, seus usos, composição farmacêutica e embalagem comercial - Google Patents

combinação de inibidor de pi3k e inibidor de c-met, seus usos, composição farmacêutica e embalagem comercial

Info

Publication number
BR112015002528A2
BR112015002528A2 BR112015002528-5A BR112015002528A BR112015002528A2 BR 112015002528 A2 BR112015002528 A2 BR 112015002528A2 BR 112015002528 A BR112015002528 A BR 112015002528A BR 112015002528 A2 BR112015002528 A2 BR 112015002528A2
Authority
BR
Brazil
Prior art keywords
inhibitor
combination
pharmaceutical composition
commercial packaging
met
Prior art date
Application number
BR112015002528-5A
Other languages
English (en)
Inventor
Caponigro Giordano
Huang Xizhong
Lehar Joseph
Wang Hui-Qin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015002528A2 publication Critical patent/BR112015002528A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BR112015002528-5A 2012-08-16 2013-08-14 combinação de inibidor de pi3k e inibidor de c-met, seus usos, composição farmacêutica e embalagem comercial BR112015002528A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683790P 2012-08-16 2012-08-16
US61/683,790 2012-08-16
PCT/US2013/054848 WO2014028566A1 (en) 2012-08-16 2013-08-14 Combination of pi3k inhibitor and c-met inhibitor

Publications (1)

Publication Number Publication Date
BR112015002528A2 true BR112015002528A2 (pt) 2018-05-22

Family

ID=49004065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002528-5A BR112015002528A2 (pt) 2012-08-16 2013-08-14 combinação de inibidor de pi3k e inibidor de c-met, seus usos, composição farmacêutica e embalagem comercial

Country Status (14)

Country Link
US (5) US20150216870A1 (pt)
EP (1) EP2885003B1 (pt)
JP (3) JP2015529194A (pt)
KR (2) KR20210049187A (pt)
CN (1) CN105050623B (pt)
AU (4) AU2013302702A1 (pt)
BR (1) BR112015002528A2 (pt)
CA (1) CA2879704A1 (pt)
ES (1) ES2901712T3 (pt)
HK (1) HK1211476A1 (pt)
IN (1) IN2015DN00528A (pt)
MX (1) MX369518B (pt)
RU (1) RU2705095C2 (pt)
WO (1) WO2014028566A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849995A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
BR112015030578A2 (pt) * 2013-06-18 2017-07-25 Novartis Ag combinações farmacêuticas
KR20230136693A (ko) 2014-07-25 2023-09-26 노파르티스 아게 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제
CN108367003B (zh) 2014-12-12 2022-01-21 麻省总医院 乳腺癌脑转移的治疗
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101532256B1 (ko) * 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PT2259800E (pt) * 2008-03-05 2014-08-06 Novartis Ag Utililização de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4- trifluorometil-piridin-2-ilamina para o tratamento de carcinoma pulmonar de não pequenas células com resistência adquirida aos moduladores do receptor de factor de crescimento epidérmico (egfr)
HUE034716T2 (hu) * 2008-05-21 2018-02-28 Incyte Holdings Corp 2-Fluor-N-metil-4-[7-(kinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamid sói és eljárások ezek elõállítására
JP2011527703A (ja) * 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100267742A1 (en) * 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
JP2013542228A (ja) * 2010-11-08 2013-11-21 ノバルティス アーゲー Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用

Also Published As

Publication number Publication date
JP2020079243A (ja) 2020-05-28
JP2018035188A (ja) 2018-03-08
HK1211476A1 (en) 2016-05-27
US20220280523A1 (en) 2022-09-08
EP2885003A1 (en) 2015-06-24
RU2705095C2 (ru) 2019-11-05
KR102245985B1 (ko) 2021-04-30
AU2013302702A1 (en) 2015-02-19
KR20210049187A (ko) 2021-05-04
AU2018201725A1 (en) 2018-04-05
AU2019226212B2 (en) 2020-05-14
US20190083500A1 (en) 2019-03-21
JP6644042B2 (ja) 2020-02-12
US20150216870A1 (en) 2015-08-06
ES2901712T3 (es) 2022-03-23
KR20150043328A (ko) 2015-04-22
AU2016238903A1 (en) 2016-10-27
AU2019226212A1 (en) 2019-09-26
RU2015108755A (ru) 2016-10-10
MX2015002005A (es) 2015-10-08
CA2879704A1 (en) 2014-02-20
US20190350935A1 (en) 2019-11-21
WO2014028566A1 (en) 2014-02-20
JP6970217B2 (ja) 2021-11-24
IN2015DN00528A (pt) 2015-06-26
CN105050623B (zh) 2018-06-12
MX369518B (es) 2019-11-11
US20200253980A1 (en) 2020-08-13
JP2015529194A (ja) 2015-10-05
EP2885003B1 (en) 2021-09-29
CN105050623A (zh) 2015-11-11

Similar Documents

Publication Publication Date Title
BR112015002528A2 (pt) combinação de inibidor de pi3k e inibidor de c-met, seus usos, composição farmacêutica e embalagem comercial
BR112016000909A2 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
BR112013005523A2 (pt) composto como inibidores de quinase c-met e seus usos
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
DK3632919T3 (da) Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering
BR112014030917A2 (pt) artigo absorvente
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
BR112014028333A2 (pt) artigos absorventes com elásticos em múltiplas camadas
BR112014028647A2 (pt) composições e métodos para modulação da expressão de bdnf
BR112014026835A2 (pt) artigo absorvente
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
BR112016013254A2 (pt) Produto higiênico e produto absorvente
BR112015009718A2 (pt) composição de matéria e artigo.
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
BR112015014598A2 (pt) artigo absorvente
CL2014000419A1 (es) Composicion de ionomero antimicrobiano y los usos del mismo
BR112016007386A2 (pt) derivados alcalinos bicíclicos e usos dos mesmos
BR112015010271A2 (pt) produto de comicronização, composição farmacêutica e seus usos
FI20126144A (fi) Puolukkauutefraktioita sisältävät kosmeettiset koostumukset
DK2912032T3 (da) 4-carboxamido-isoindolinonderivater som selektive parp-1-hæmmere
BR112015007217A2 (pt) compostos e usos do composto
IL243982A0 (en) History of piperidine urea, their preparation and pharmaceutical preparations containing them
IL241513A0 (en) History of piperazine, their preparation and pharmaceutical preparations containing them
BR112015002652A2 (pt) composições de poliolefina e artigos fabricados destas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements